These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 31115858)

  • 21. PBPK-based translation from preclinical species to humans for the full-size IgG therapeutic efalizumab.
    Franz M; Jairam RK; Kuepfer L; Hanke N
    Front Pharmacol; 2024; 15():1418870. PubMed ID: 39411068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Prediction of Monoclonal Antibody Tumor Disposition.
    Bordeau BM; Polli JR; Schweser F; Grimm HP; Richter WF; Balthasar JP
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancer.
    Abuqayyas L; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2012 Dec; 39(6):683-710. PubMed ID: 23184417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Whole-Body Disposition and Physiologically Based Pharmacokinetic Modeling of Adeno-Associated Viruses and the Transgene Product.
    Liu S; Chowdhury EA; Xu V; Jerez A; Mahmood L; Ly BQ; Le HK; Nguyen A; Rajwade A; Meno-Tetang G; Shah DK
    J Pharm Sci; 2024 Jan; 113(1):141-157. PubMed ID: 37805073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of human CNS pharmacokinetics using a physiologically-based pharmacokinetic modeling approach.
    Yamamoto Y; Välitalo PA; Wong YC; Huntjens DR; Proost JH; Vermeulen A; Krauwinkel W; Beukers MW; Kokki H; Kokki M; Danhof M; van Hasselt JGC; de Lange ECM
    Eur J Pharm Sci; 2018 Jan; 112():168-179. PubMed ID: 29133240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment and Confirmation of Species Difference in Nonlinear Pharmacokinetics of Atipamezole with Physiologically Based Pharmacokinetic Modeling.
    Li Z; Gao Y; Yang C; Xiang Y; Zhang W; Zhang T; Su R; Lu C; Zhuang X
    Drug Metab Dispos; 2020 Jan; 48(1):41-51. PubMed ID: 31699808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Translational physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies.
    Naware S; Bussing D; Shah DK
    J Pharmacokinet Pharmacodyn; 2024 Oct; 51(5):493-508. PubMed ID: 37558929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection.
    Pasquiers B; Benamara S; Felices M; Nguyen L; Declèves X
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies.
    Cao Y; Balthasar JP; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2013 Oct; 40(5):597-607. PubMed ID: 23996115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs.
    Davda JP; Jain M; Batra SK; Gwilt PR; Robinson DH
    Int Immunopharmacol; 2008 Mar; 8(3):401-13. PubMed ID: 18279794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.
    Wang J; Iyer S; Fielder PJ; Davis JD; Deng R
    Biopharm Drug Dispos; 2016 Mar; 37(2):51-65. PubMed ID: 25869767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a PBPK model for monoclonal antibodies and simulation of human and mice PBPK of a radiolabelled monoclonal antibody.
    Heiskanen T; Heiskanen T; Kairemo K
    Curr Pharm Des; 2009; 15(9):988-1007. PubMed ID: 19275663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interstitial IgG antibody pharmacokinetics assessed by combined in vivo- and physiologically-based pharmacokinetic modelling approaches.
    Eigenmann MJ; Karlsen TV; Krippendorff BF; Tenstad O; Fronton L; Otteneder MB; Wiig H
    J Physiol; 2017 Dec; 595(24):7311-7330. PubMed ID: 28960303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inter-Antibody Variability in the Clinical Pharmacokinetics of Monoclonal Antibodies Characterized Using Population Physiologically Based Pharmacokinetic Modeling.
    Kumar M; Lanke S; Yadav A; Ette M; Mager DE; Shah DK
    Antibodies (Basel); 2024 Jul; 13(3):. PubMed ID: 39051330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation of Antibody Pharmacokinetics in the Brain Following Intra-CNS Administration and Development of PBPK Model to Characterize the Data.
    Wu S; Chang HY; Chowdhury EA; Huang HW; Shah DK
    AAPS J; 2024 Mar; 26(2):29. PubMed ID: 38443635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physiologically based pharmacokinetic (PBPK) model that describes enhanced FcRn-dependent distribution of monoclonal antibodies (mAbs) by pI-engineering in mice.
    Naoi S; Yamane M; Nemoto T; Kato M; Saito R; Tachibana T
    Drug Metab Pharmacokinet; 2023 Dec; 53():100506. PubMed ID: 38029470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model.
    Chetty M; Li L; Rose R; Machavaram K; Jamei M; Rostami-Hodjegan A; Gardner I
    Front Immunol; 2014; 5():670. PubMed ID: 25601866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.
    Garg A; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2007 Oct; 34(5):687-709. PubMed ID: 17636457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Translational pharmacokinetics of a novel bispecific antibody against Ebola virus (MBS77E) from animal to human by PBPK modeling & simulation.
    Zhang W; Xiang Y; Wang L; Wang F; Li G; Zhuang X
    Int J Pharm; 2022 Oct; 626():122160. PubMed ID: 36089211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of a catenary PBPK model to predict the disposition of "catch and release" anti-PCSK9 antibodies.
    Glassman PM; Balthasar JP
    Int J Pharm; 2016 May; 505(1-2):69-78. PubMed ID: 27041125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.